New drug sequence aims to outsmart resistant breast cancer
Disease control
Recruiting now
This study tests whether giving two different antibody drug conjugates (Dato-DXd and T-DXd) one after the other can shrink tumors in people with HER2-negative metastatic breast cancer whose cancer has already progressed after prior antibody drug conjugate therapy. About 357 parti…
Phase: PHASE2 • Sponsor: Ana C Garrido-Castro, MD • Aim: Disease control
Last updated Apr 26, 2026 19:35 UTC